Table 3.
Univariate and multivariate analyses of PFS in CT group.
| Variables | Univariate | p Value a | Multivariate | p Value a |
|---|---|---|---|---|
| HR (95% CI) | aHR (95% CI) | |||
| Age | 0.321 | 0.556 | ||
| ≧65 | Reference | |||
| <65 | 1.393 (0.722–2.687) | 1.249 (0.597–2.613) | ||
| Gender, n (%) | 0.947 | 0.304 | ||
| Male | Reference | |||
| Female | 1.022 (0.535–1.951) | 1.689 (0.622–4.585) | ||
| Smoking status, n (%) | 0.714 | 0.545 | ||
| Never smokers | Reference | |||
| Former or current smokers | 1.129 (0.589–2.166) | 1.367 (0.497–3.761) | ||
| ECOG PS, n (%) | 0.924 | 0.483 | ||
| 0–1 | Reference | |||
| 2–4 | 0.995 (0.373–2.448) | 1.448 (0.515–4.073) | ||
| Stage, n (%) | 0.042 | 0.008 | ||
| Stage 4A | Reference | |||
| Stage 4B | 2.046 (1.027–4.080) | 2.799 (1.309–5.985) | ||
| Regimen | 0.274 | 0.194 | ||
| Cisplatin | Reference | |||
| Carboplatin | 0.647 (0.297–1.412) | 0.553 (0.227–1.350) | ||
| Driver mutation (EGFR/ALK/ROS1) | 0.305 | 0.071 | ||
| Yes | Reference | |||
| No | 1.391 (0.741–2.613) | 1.979 (0.943–4.153) | ||
| Bevacizumab | 0.259 | 0.120 | ||
| RP | Reference | |||
| BB | 0.679 (0.347–1.329) | 0.571 (0.282–1.156) |
a
By Cox proportional hazard model.
aHR, adjusted hazard ratio; ALK, anaplastic lymphoma kinase; BB, bevacizumab biosimilar; CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; EGFR, epidermal growth factor receptor; HR, hazard ratio; PFS, progression-free survival; ROS1, ROS proto-oncogene 1; RP, reference product.